Crossmark

Clinical and urodynamic benefit of adding antimuscarinics after a loss of efficacy of intradetrusor botulinum toxin in patients with multiple sclerosis

Crossref DOI link: https://doi.org/10.1007/s00345-025-05655-9

Published Online: 2025-05-06

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Haegel, Adrien https://orcid.org/0009-0000-9917-5799
Chesnel, Camille

Teng, Maëlys

Vivier, Magdaline

Noël, Camille

Amarenco, Gérard

Hentzen, Claire

Adrien, Haegel
License Information

Text and Data Mining valid from 2025-05-06

Version of Record valid from 2025-05-06
More Information

Article History

Received: 4 January 2025

Accepted: 22 April 2025

First Online: 6 May 2025

Declarations

:

: The authors declare no competing interests.

Document is current

Any future updates will be listed below